Medco kicks off critical pivotal inclisiran program
By Michael Fitzhugh
Staff Writer
Staff Writer
Patient dosing has begun in the first of four pivotal trials key to The Medicines Co.'s big bet on inclisiran, a cardiovascular-focused RNAi therapy critical to the drugmaker's return to profitability.
